SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher ...

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

A Cell Metabolism study reveals that GIPR signaling in oligodendrocytes enhances brain access and weight-loss efficacy of GLP ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, ...

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ ...

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher risk of cardiovascular and ...

More evidence shows a risk between GLP-1 drugs and vision risks. A study in JAMA Network Open adds more evidence linking ...

In 2025, Släcka introduces a functional beverage designed to combat mid-afternoon cravings by offering a healthier ...